Qlt Inc (QLTI) 1.43 $QLTI QLT Inc. (QLTI) in Focus:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Qlt Inc (QLTI) 1.43 $QLTI

QLT Inc. (QLTI) in Focus: Stock Adds 6.9% in Session
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:05AM CDT
QLT Inc. (QLTI) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
QLTI: 1.43 (unch)

Aegerion (AEGR) Q2 Loss Wider than Expected, View Intact
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 2:35PM CDT
Aegerion (AEGR) reported a loss of 87 cents per share in the second quarter of 2016, which was wider than the Zacks Consensus Estimate of a loss of 25 cents.
QLTI: 1.43 (unch), ANIP: 59.74 (-1.12), GERN: 2.69 (unch), AEGR: 1.63 (+0.01)

QLT Announces Second Quarter 2016 Results
GlobeNewswire - Tue Aug 09, 3:08PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" reported financial results today for the second quarter ended June 30, 2016. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

QLT Announces Results of Annual General Meeting of Shareholders
GlobeNewswire - Fri Jun 17, 3:05PM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on June 17, 2016 (the "Meeting" .
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:23PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has entered into a definitive merger agreement with QLT Inc. (QLTI).
ABT: 42.02 (-0.81), JNJ: 119.34 (-0.13), QLTI: 1.43 (unch), AEGR: 1.63 (+0.01)

Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger
GlobeNewswire - Wed Jun 15, 6:00AM CDT
--Strategic Merger Creates Well-Capitalized, Global Biopharmaceutical Organization with Diverse Portfolio of Two Commercialized Rare Disease Programs and a Phase 3 Ready Ultra-Orphan Development Program Addressing Significant Unmet Medical Need--
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01), AEGR: 1.63 (+0.01)

QLT Inc. reports 1Q loss
Automated Insights - Thu May 05, 6:27AM CDT
VANCOUVER, British Columbia (AP) _ QLT Inc. (QLTI) on Thursday reported a loss of $21.9 million in its first quarter.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

QLT Announces First Quarter 2016 Results
GlobeNewswire - Thu May 05, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" reported financial results today for the first quarter ended March 31, 2016. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

QLT Terminates $20 Million Private Placement
GlobeNewswire - Mon May 02, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that it has terminated the previously announced US$20 million private placement in QLT. The Company's Board of Directors (the "Board" has determined that it would not be in the best interests of QLT to dilute its existing shareholders.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

QLT Inc. Completes Enrollment in its Natural History Study
GlobeNewswire - Fri Apr 22, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI); (TSX:QLT) ("QLT" or the "Company" announced today completion of enrollment in its retrospective, uncontrolled, multicenter Natural History Study in subjects with Inherited Retinal Disease (IRD) phenotypically diagnosed with Retinitis Pigmentosa (RP) or Leber Congenital Amaurosis (LCA) due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) gene mutations. The objective of the retrospective, open label study is to gather data on the natural progression of the disease in subjects over time, including from childhood through to adulthood. The study included both subjects who had previously received treatment in QLT-sponsored clinical trials with QLT's synthetic oral retinoid product, QLT091001, as well as subjects who had not received any prior therapeutic treatment. For subjects who had received prior treatment with QLT091001, the study included a retrospective review of subjects' medical records prior to and after treatment with QLT091001.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
QLTI: 1.43 (unch), LNCO: 0.12 (unch), AEGR: 1.63 (+0.01), TWTR: 19.21 (+0.83)

5 Stocks Near 52-Week Lows But Still Worth Buying
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:31AM CDT
These stocks are priced close to their 52-week low at the moment and offer an excellent bargain to investors.
QLTI: 1.43 (unch), LNCO: 0.12 (unch), GOOGL: 789.85 (-2.07), AEGR: 1.63 (+0.01), TWTR: 19.21 (+0.83)

QLT Announces Date of Special Distribution to Shareholders
GlobeNewswire - Mon Apr 04, 7:37AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" is pleased to announce that its previously announced special distribution (the "Special Distribution" of common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc., or cash in lieu thereof, to QLT shareholders will complete on April 5, 2016 (the "Distribution Date" .
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01), ARLZ: 4.97 (-0.07)

Should QLT Inc. (QLTI) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:47AM CDT
QLT Inc. has actually seen rising estimates over the past one month and looks well positioned for a solid gain, but has been overlooked by investors
QLTI: 1.43 (unch)

Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 7.38 (-0.08), QLTI: 1.43 (unch), FOMX: 8.30 (-0.35), AAVL: 4.14 (-0.18), REGN: 392.55 (-2.67)

QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
GlobeNewswire - Fri Feb 05, 12:30PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announces that it has acquired 7,200,000 common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez.
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01), ARLZ: 4.97 (-0.07), POZN: 5.94 (-0.43)

Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.43 (unch), ISIS: 57.56 (-0.28), ONCE: 56.58 (+0.26), SHPG: 187.18 (-3.04), SCMP: 10.96 (-0.05), GNST: (), CLBS: 4.84 (-0.13)

QLT Announces Results of Annual Meeting of Shareholders
GlobeNewswire - Tue Jan 12, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on January 8, 2016 (the "Meeting" .
QLTI: 1.43 (unch), QLT.TO: 1.90 (-0.01)

World Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/n7h2f2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Leber Congenital Amaurosis (LCA) Overview - Therapeutics Development - Pipeline Products for Leber Congenital Amaurosis (LCA) - Overview - Pipeline Products for Leber Congenital Amaurosis (LCA) - Comparative Analysis - Leber Congenital Amaurosis (LCA) - Therapeutics under Development by Companies - Leber Congenital Amaurosis (LCA) - Therapeutics under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Leber Congenital Amaurosis (LCA) - Products under Development by Companies - Leber Congenital Amaurosis (LCA) - Products under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n7...congenital
QLTI: 1.43 (unch), ONCE: 56.58 (+0.26), APHB: 1.70 (-0.01)

QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction
GlobeNewswire - Mon Dec 28, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announced that it has called a special meeting of its shareholders (the "Special Meeting" to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization" . As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. ("Aralez" to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada.
QLTI: 1.43 (unch), TRX.VN: 1.250 (-0.070), QLT.TO: 1.90 (-0.01), ARLZ: 4.97 (-0.07), POZN: 5.94 (-0.43)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

Steel Dynamics Insider Sell: Key Insights and Future Outlook

Updated Category News Views 91

Understanding Recent Insider Transactions at Steel Dynamics In a noteworthy development, James Stanley Anderson, the Senior Vice President of Steel Dynamics (NASDAQ: STLD), executed a substantial sell-off of shares, raising eyebrows among investors and industry analysts alike. This insider transaction, reported through an SEC filing, includes the sale of 10,000 shares,...

Continue Reading
Final Cash Distributions for iShares Premium Money Market ETF

Updated Category News Views 182

Final Cash Distributions Announced BlackRock Asset Management Canada Limited has recently revealed significant cash distributions for the iShares Premium Money Market ETF. This announcement, which is essential for investors looking to optimize their financial strategies, includes details on the cash distributions that will be made available for unitholders. Distribution...

Continue Reading
Sina Corporation Investors Encouraged to Join Class Action

Updated Category News Views 161

Sina Corporation Investors Encouraged to Join Class Action Attention investors of Sina Corporation (NASDAQ:SINA): If you've experienced significant financial losses related to the company's stock, you have a valuable opportunity to take action. A class action lawsuit has been initiated against Sina and its executives. Understanding the Class Action The lawsuit has been...

Continue Reading
Talisker’s Bralorne Gold Project Shows Thriving Ore Sorting Potential

Updated Category News Views 258

Talisker’s Innovative Approach to Ore Sorting Talisker Resources Ltd. is excited to share that promising outcomes have surfaced from its initial testing of ore sorting technologies at the Bralorne Gold Project. This flagship site, situated in British Columbia, is undergoing a revitalization aimed at enhancing gold recovery processes. The success of these technologies...

Continue Reading
Avalanche Experiences Significant Price Surge of 5.53% in One Day

Updated Category News Views 79

Avalanche Sees Impressive Market Performance Avalanche (AVAX) has demonstrated a remarkable surge in the cryptocurrency market, with its price climbing 5.53% in just 24 hours, now sitting at $29.11. This impressive rise is part of a larger trend, as the coin has seen a weekly increase of over 10%, up from $26.40. Notably, the coin has reached an all-time high of $144.96,...

Continue Reading